Business Wire

MA-PTC

1.7.2020 22:02:08 CEST | Business Wire | Press release

Share
Inaugural Virtual Edition of LiveWorx Digital Transformation Event Draws Thousands

For the first time in the event’s decade-long history, the annual LiveWorx® digital transformation event took place online, uniting tens of thousands of industry leaders across the world. Chaired by presenting sponsor, PTC (NASDAQ: PTC), the one-day event featured more than 120 sessions spanning topics ranging from Augmented Reality (AR) , Artificial Intelligence (AI), 5G, Robotics, Software as a Service (SaaS) , Industrial Internet of Things (IIoT) , Product Lifecycle Management (PLM) , and Computer-Aided Design (CAD) , and more.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200701005892/en/

“This year’s virtual event brought to life the magic, excitement, and drive for transformative change that we all experience at the annual in-person version,” said Jim Heppelmann, President and CEO, PTC. “I was particularly pleased to see the force of change magnified inside and outside of this year’s event. For the global society, 2020 has been a year of challenge and growth. I look forward to seeing how this year’s energy and drive will be matched in next year’s event.”

Energizing Change

In support of movements and causes that shape the world in which the technology community operates, the LiveWorx event recognized four charities as beneficiaries for donations stemming from attendee actions throughout the event. For each attendee who entered the virtual Networking Lounge, shared their experience on social media using #LiveWorx, or completed an online scavenger hunt, approximately $1 per action was donated to charities including WWF - World Wildlife Fund , International Rescue Committee , Save the Children , and Black Girls CODE . Following the event’s final keynote session, all donations were matched by presenting sponsor, PTC.

“Bringing to life the Black Girls CODE story during this year’s LiveWorx event enabled us to raise awareness of our mission across the globe, and reinforce why we need to confront this crisis today to ensure a brighter and more inclusive tomorrow,” said Kimberly Bryant, Founder and CEO, Black Girls CODE. “While there is still a lot of work to do, I am proud to have had the opportunity to share this message, and will continue to champion inclusion for all of the women entering the STEM community.”

As part of its mission to foster inclusion across the technology industry, LiveWorx continuously endeavors to reflect more gender, racial, and geographic diversity in STEM fields represented at the event. At this year’s event, 21% of presenters identified as female or non-binary, 27% of presenters were Black, Indigenous, and People of Color (BIPOC), and 23% of presenters resided outside the United States.

Thriving in the ‘New Normal’

Over the course of the one-day event, attendees heard from technology experts across the community, including the following keynote headliners:

To replay LiveWorx keynotes, track spotlights, and more, access the LiveWorx 2020 Content Archive . Event replays will be available through Spring 2021.

Major Product Announcements Put Industrial Enterprise Technology at Precipice of Future

Coinciding with the momentum and excitement surrounding LiveWorx 20, PTC shared key product releases from its ThingWorx® IIoT Platform , and Windchill® PLM Software offerings; recent advancements following November’s acquisition of the Onshape® SaaS technology ; and the launch of the new Factory Insights as a Service product in collaboration with sponsors Rockwell Automation and Microsoft.

Alongside this year’s Title Sponsor, Analog Devices, 11 companies supported LiveWorx 20 including Pinnacle Sponsors Ansys, AT&T Business, Ericsson, EY, and Transition Technologies; and Premier Sponsors Archer Grey, Deloitte, EPLAN, Hewlett Packard Enterprise, and Kalypso.

About PTC (NASDAQ: PTC)

PTC enables global manufacturers to realize double-digit impact with software solutions that enable them to accelerate product and service innovation, improve operational efficiency, and increase workforce productivity. In combination with an extensive partner network, PTC provides customers flexibility in how its technology can be deployed to drive digital transformation – on premises, in the cloud, or via its pure SaaS platform. At PTC, we don’t just imagine a better world, we enable it.

PTC.com @PTC Blogs

PTC, LiveWorx, ThingWorx, Windchill, Onshape, and the PTC logo are trademarks or registered trademarks of PTC Inc. and/or its subsidiaries in the United States and other countries.

Link:

ClickThru

Social Media:

https://www.facebook.com/liveworxevent

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release

Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye